A recent study by a team at Unilever has demonstrated the predictive power of NAM approaches for the comprehensive safety assessment of compounds by combining in vitro models with advanced computational techniques. They used the aProximate™ proximal tubule cell model to assess potential nephrotoxicity and renal transport kinetics.
During this webinar you will hear from our 3 panelists discuss regulatory, technology and scientific perspectives to gain insights, into accelerating your compound through the clinical development pipeline with a focus on retina.
Date: Wednesday 19th June 2024
Speakers:
June 19, 2024
Share on social media:
Don't miss out on our latest innovations: follow us on Linkedin